Prevalence of human papillomavirus infection in women in Benin, West Africa

Virology Journal

Volumn 8, Issue , 2011, Pages

  Piras, Franca ^a   Piga, Michela ^b   De Montis, Antonella ^c   Zannou, Ahissou R F ^d   Minerba, Luigi ^a   Perra, Maria T ^a   Murtas, Daniela ^a   Atzori, Manuela ^c   Pittau, Marco ^c   Maxia, Cristina ^a   Sirigu, Paola ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b SS Trinit Hospital   (Italy)

^c Research Laboratories   (Italy)

^d MINISTÈRE DE LA SANTÉ   (Benin)

Author keywords

Benin; cervical cancer; human papillomavirus; Pap test; prevention

Indexed keywords

VIRUS DNA; VIRUS PROTEIN;

ADOLESCENT; ADULT; AFRICA; AGED; ARTICLE; CANCER IMMUNIZATION; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; MAJOR CLINICAL STUDY; MIXED INFECTION; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PREVALENCE; UTERINE CERVIX CANCER; VACCINATION; VIRUS GENOME; VIRUS IDENTIFICATION; WART VIRUS; BENIN; CLASSIFICATION; CYTOLOGY; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; PAPILLOMA VIRUS; POLYMERASE CHAIN REACTION; UTERINE CERVIX; VAGINA SMEAR; VIROLOGY;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

ADOLESCENT; ADULT; AGED; BENIN; CERVIX UTERI; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PREVALENCE; VAGINAL SMEARS; VIRAL PROTEINS; YOUNG ADULT;

EID: 80755189640     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-514     Document Type: Article

References (38)

1. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre), Human Papillomavirus and Related Cancers, Benin. Summary Report 2010 http://www.who.int/hpvcentre
2. HPV screening for cervical cancer in rural India. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N, Dinshaw KA, N Engl J Med 2009 360 1385 1394 10.1056/NEJMoa0808516 19339719
3. The role of the human papillomavirus (HPV) vaccine in developing countries. Kling M, Zeichner JA, Int J Dermatol 2010 49 377 379 10.1111/j.1365-4632.2010.04316.x 20465688
4. Effective screening programs for cervical cancer in low- and middle-income developing countries. Sankaranarayanan R, Budukh A, Rajkumar R, Bull World Health Organ 2001 79 954 962 11693978 (Pubitemid 33027175)
5. Preventing cervical cancer in the developing world. Katz IT, Wright AA, N Engl J Med 2006 354 1110 10.1056/NEJMp068031 16540609
6. The cervical cancer epidemic that screening has prevented in the UK. Peto J, Gilham C, Fletcher O, Matthews FE, Lancet 2004 364 249 256 10.1016/S0140-6736(04)16674-9 15262102 (Pubitemid 38942814)
7. zur Hausen H, Infections Causing Human Cancer Weinheim: WILEY-VCH Verlag GmbH & Co. KgaA 2006
8. HPV-related carcinogenesis: basic concepts, viral types and variants. Lizano M, Berumen J, García-Carrancá A, Arch Med Res 2009 40 428 434 10.1016/j.arcmed.2009.06.001 19853182
9. Human papillomavirus and cervical cancer. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S, Lancet 2007 370 890 907 10.1016/S0140-6736(07)61416-0 17826171 (Pubitemid 47371147)
10. Prevalence of human papillomavirus genotypes and their variants in high risk West Africa women immigrants in South Italy. Tornesello ML, Duraturo ML, Buonaguro L, Vallefuoco G, Piccoli R, Palmieri S, Buonaguro FM, Infect Agent Cancer 2007 2 1 10.1186/1750-9378-2-1 17201927
11. The 2001 Bethesda System: terminology for reporting results of cervical cytology. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T Jr, Young N, Forum Group Members, Bethesda 2001 Workshop, JAMA 2002 287 2114 2119 10.1001/jama.287.16.2114 11966386 (Pubitemid 34437346)
12. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson, JAMA 2002 287 2120 2129 10.1001/jama.287.16.2120 11966387 (Pubitemid 34437347)
13. Gestione della paziente con il Pap-test anormale. Linee Guida Edizione 2006. Societa' Italiana di Colposcopia e Patologia Cervico Vaginale, La Colposcopia in Italia Modena: Artioli Editore Poligrafico Artioli 2006
14. Bishop A, Sherris J, Tsu V, Cervical Dysplasia Treatment in Developing Countries: a Situation Analysis Seattle: PATH 1995
15. Cervical cancer: evolving prevention strategies for developing countries. Bishop A, Wells E, Sherris J, Tsu V, Crook B, Reproductive Health Matters 1995 6 60 71
16. McIntosh N, Blumenthal P, Blouse A, Cervical Cancer Prevention Guidelines for Low-resource Settings Baltimore: JHPIEGO Corporation 2001
17. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D, 2006 ASCCP-Sponsored Consensus Conference, J Low Genit Tract Dis 2007 4 201 222 (Pubitemid 47530909)
18. Validation of high-risk HPV tests for primary cervical screening. Meijer CJ, Berkhof H, Heideman DA, Hesselink AT, Snijders PJ, J Clin Virol 2009 46 Suppl 3 1 4 20129067
19. Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinsky SM, Cancer Cells 1989 7 209 214
20. The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ, J Gen Virol 1995 76 1057 1062 10.1099/0022-1317-76-4-1057 9049358
21. DNA-EIA to detect high and low risk HPV genotypes in cervical lesions with E6/E7 primer mediated multiplex PCR. Clavel C, Rihet S, Masure M, Chypre C, Boulanger JC, Quereux C, Birembaut P, J Clin Pathol 1998 51 38 43 10.1136/jcp.51.1.38 9577370 (Pubitemid 28122584)
22. Human papillomavirus testing methods. Hubbard RA, Arch Pathol Lab Med 2003 127 940 945 12873165 (Pubitemid 36994852)
23. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA, Science 1988 239 487 491 10.1126/science.2448875 2448875 (Pubitemid 18084310)
24. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Clifford GM, Smith JS, Aguado T, Franceschi S, Br J Cancer 2003 89 101 105 10.1038/sj.bjc.6601024 12838308 (Pubitemid 36897943)
25. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S, Br J Cancer 2003 88 63 73 10.1038/sj.bjc.6600688 12556961 (Pubitemid 36241220)
26. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Clifford GM, Gallus S, Herrero R, Mũoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjosé S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJ, Franceschi S, IARC HPV Prevalence Surveys Study Group, Lancet 2005 366 991 998 10.1016/S0140-6736(05)67069-9 16168781 (Pubitemid 41323035)
27. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM, Cancer Epidemiol Biomarkers Prev 2005 14 1157 1164 10.1158/1055-9965.EPI-04-0812 15894666 (Pubitemid 40656461)
28. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Mũoz N, Bosch FX, Lancet Infectious Diseases 2007 7 453 459 10.1016/S1473-3099(07) 70158-5 17597569 (Pubitemid 46962343)
29. Epidemiology and natural history of human papillomavirus infection and type-specific implications in cervical neoplasia. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Mũoz N, Vaccine 2008 26 1 16 18847553
30. Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. Thomas JO, Herrero R, Omigbodun AA, Ojemakinde K, Ajayi IO, Fawole A, Oladepo O, Smith JS, Arslan A, Mũoz N, Snijders PJ, Meijer CJ, Franceschi S, Br J Cancer 2004 90 638 645 10.1038/sj.bjc.6601515 14760378 (Pubitemid 38297204)
31. Human papillomavirus genotype distribution and cervical squamous intraepithelial lesions among high-risk women with and without HIV-1 infection in Burkina Faso. Didelot-Rousseau MN, Nagot N, Costes-Martineau V, Vallès X, Ouedraogo A, Konate I, Weiss HA, Van de Perre P, Mayaud P, Segondy M, Yerelon Study Group, Br J Cancer 2006 95 355 362 10.1038/sj.bjc.6603252 16832413 (Pubitemid 44187597)
32. Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention. Barzon L, Giorgi C, Buonaguro FM, Pal G, Infectious Agents and Cancer 2008 3 14 10.1186/1750-9378-3-14 19087272
33. Cervical human papillomavirus infection in the female population in Barcelona, Spain. de Sanjose S, Almirall R, Lloveras B, Font R, Diaz M, Mũoz N, Catal I, Meijer CJ, Snijders PJ, Herrero R, Bosch FX, Sex Transm Dis 2003 30 788 793 10.1097/01.OLQ.0000080177.82204.E0 14520179 (Pubitemid 37229490)
34. Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies. Harper DM, Williams KB, Discov Med 2010 10 7 17 20670593
35. Prevalence of human papillomavirus infection and genotype distribution among high-risk Korean women for prospecting the strategy of vaccine development. Rhee JE, Shin MY, Kim CM, Kee HY, Chung JK, Min SK, Kim SJ, Jang DH, Kim SS, Choi BS, Virol J 2010 7 201 10.1186/1743-422X-7-201 20738861
36. Prophylactic human papillomavirus vaccines to prevent cervical cancer: review of the Phase II and III trials. Harper DM, Therapy 2008 5 313 324 10.2217/14750708.5.3.313 (Pubitemid 351781149)
37. Human papillomavirus vaccination - reasons for caution. Haug CJ, N Engl J Med 2008 359 861 862 10.1056/NEJMe0804638 18716305
38. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, Krogh G, Lehtinen M, Malm C, Tamms GM, Giacoletti K, Lupinacci L, Railkar R, Taddeo FJ, Bryan J, Esser MT, Sings HL, Saah AJ, Barr E, Br J Cancer 2006 95 1459 1466 10.1038/sj.bjc.6603469 17117182 (Pubitemid 44863348)